treatment at 1 and 3 months respectively. Graph I (A,B) showed the discontinuation reasons. 36 out of 92 women were evaluated at 6 months with a high drug adherence (median MMAS-4 score of 0 (range 0-2) ). At 6 months follow-up patient's satisfaction was high, infact median PGI-I and S-VAS were 2 (range 1-4) and 8 (2-10) respectively. At 1,3,6 months OABq-sf score showed a statistically significant improvement with a baseline median score of 36 (range 19-99), of 9 (range 7-24) at 6 months (p¼0.001). Graph 1C showed an improvement of all the OAB symptoms at 1 and 3 months, but they were stable at 6 months. Furthermore a statistically significant decrement of the mean number of pads/die was evident at 6 month (1.45AE1.58 vs 0.57 AE 0.98 p<0.0001).UF results showed no statistical changes at 1 month and at 6 months.The results are not different in women with OAB naïve and women with OAB refractory to antimuscarinic drugs CONCLUSIONS: Mirabegron 50mg showed significant subjective and objective efficacy with a high in women with OAB at 1 and 3 months of treatment. For the low side-effects and its impact on QoL, it can be considered the first line therapy in these patients. Long term results are mandatory for patients perspective and counselling for tailored therapy.
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RESULTS: Of the 16 FS, 100% answered that doctors should be alerted of their post-surgical complications (question 1). And, of the lecture attendants, 95.6% also stated they wished to be alerted (10 skipped). Based on the second question on reasons for why we do not contact each other when we are made aware of a long-term complication, 60% of the FS and 53% of the attendants believed that a surgeon might not want to offend or lose a referral base. 13% of FS and 21% of attendants believed that surgeons not knowing his/her own outcomes data was a possible reason. 13% of surgeons and 21% of the attendants believe that the unwillingness to want to increase the operative surgeon 0 s legal risk could be a reason. 20% of surgeons and 17% of attendants believed that a surgeon might not think feedback decreases complication risks. Lastly 73% of FS and 72% of attendants believed that a surgeon being too busy to track down whom to contact is a primary reason. As far as the best method of providing this long-term tracking data (question 3), 94% of the FS and 84% of the attendants answered that a phone call was the best means for this feedback. The practicality of providing this feedback is hampered by unintended consequences of legal mandates related to patient protected health information.
CONCLUSIONS: Despite legal barriers in place prohibiting this process, this data suggest that operative surgeons and most urology care providers are interested in receiving information on their long-term post-surgical complications. (GEC) is required for maintenance of the glomerular filtration barrier (GFB) structure and function. Disruption of VEGF homeostasis has been implicated in various types of glomerular diseases. However, current therapies neither specifically target the glomerulus nor the VEGF pathway but in addition present multiple side effects. Therefore, identification of new approaches aimed at restoring local VEGF remains a potential therapeutic target to treat glomerular disease. We previously showed that amniotic fluid stem cells (AFSC) are renoprotective in Alport Syndrome (AS), a model of CKD. They home within the diseased glomeruli and secrete extracellular vesicles (EVs). EVs play key role in stem cell mediated paracrine function, including the kidney. Herein, we demonstrate that AFSC derived EVs regulate VEGF/VEGFRs signaling balance in AS GEC via modulation of sFlt1, the soluble isoform of VEGFR1.
METHODS: We measured VEGF activity in AS glomeruli by WB. We assessed VEGF/VEGF-Rs activity in GEC, including the sFlt1. We characterized AFSC-EVs cargo by FACS and by miRs arrays and evaluated their potential to affect VEGF biology in GEC.
RESULTS: Glomeruli from AS mice showed increased VEGF activity through increased phosphorylation of VEGFR-2 early on Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e531
